These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8196151)

  • 1. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
    Onaka H; Hirota Y; Kita Y; Tsuji R; Ishii K; Ishimura T; Kawamura K
    Jpn Circ J; 1994 Feb; 58(2):100-6. PubMed ID: 8196151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
    Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
    J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
    Nakamura Y; Yamaoka O; Uchida K; Morigami N; Sugimoto Y; Fujita T; Inoue T; Fuchi T; Hachisuka M; Ueshima H; Shimakawa H; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):475-83. PubMed ID: 8924063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
    Watanabe K; Sekiya M; Ikeda S; Miyagawa M; Hashida K
    Am Heart J; 1996 Jul; 132(1 Pt 1):23-9. PubMed ID: 8701872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate.
    Yui Y; Kawai C; Hosoda S
    Ann N Y Acad Sci; 1995 Jan; 748():208-16. PubMed ID: 7695166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Lee YJ; Daida H; Yokoi H; Miyano H; Takaya J; Sakurai H; Mokuno H; Yamaguchi H
    Jpn Heart J; 1996 May; 37(3):327-32. PubMed ID: 8774625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty.
    Tenda K; Saikawa T; Maeda T; Sato Y; Niwa H; Inoue T; Yonemochi H; Maruyama T; Shimoyama N; Aragaki S
    Jpn Circ J; 1993 Aug; 57(8):789-95. PubMed ID: 8355396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
    Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
    Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina].
    Kishi K; Hiasa Y; Tanaka H; Tanimoto M; Kinoshita M; Shinohara A; Wada T; Aihara T
    J Cardiol; 1996 Aug; 28(2):79-84. PubMed ID: 8814525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty.
    Corcos T; David PR; Val PG; Renkin J; Dangoisse V; Rapold HG; Bourassa MG
    Am Heart J; 1985 May; 109(5 Pt 1):926-31. PubMed ID: 3158187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Take S; Matsutani M; Ueda H; Hamaguchi H; Konishi H; Baba Y; Kawaratani H; Sugiura T; Iwasaka T; Inada M
    Am J Cardiol; 1997 Apr; 79(8):1097-9. PubMed ID: 9114771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
    Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
    Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.